The U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research issued a refusal‑to‑file letter on February 10, 2026, rejecting Moderna’s application for its investigational seasonal influenza vaccine, mRNA‑1010. The agency cited the trial’s comparator arm as not meeting its definition of an adequate and well‑controlled study, even though no safety or efficacy concerns were identified.
Moderna’s mRNA‑1010 is a cornerstone of the company’s plan to broaden its portfolio beyond COVID‑19. The setback places Moderna behind competitors such as Pfizer and GSK, who already have established flu vaccine products in the U.S. A delayed U.S. launch also postpones revenue that would support the company’s 2026 guidance and the development of a combined flu/COVID‑19 vaccine that relies on the mRNA‑1010 component.
The refusal centers on the use of a licensed standard‑dose influenza vaccine as the comparator in the Phase 3 study. Moderna had previously discussed and agreed on this design with the FDA’s CBER before initiating the trial, and the agency’s letter notes that the comparator did not meet its “best‑available standard of care” criteria. Importantly, the letter confirms that the data did not reveal any safety or efficacy issues.
In response, Moderna has requested a Type A meeting with the FDA to review the refusal and outline a path forward. CEO Stéphane Bancel emphasized that the decision “does not reflect any safety or efficacy concerns” and that the company remains committed to advancing the vaccine. President Stephen Hoge described the rejection as a “complete stunner,” noting the prior agreement with the FDA on the trial design.
The announcement was met with a negative market reaction, reflecting investor concern over the delay in U.S. approval and the potential impact on the company’s revenue trajectory. Analysts highlighted that the regulatory hurdle could widen the gap between Moderna and its competitors, while also noting that international reviews in the EU, Canada, and Australia are still underway and may provide a partial offset to the U.S. setback.
Moderna’s broader strategy includes a five‑year partnership with Mexico to transfer mRNA technology for respiratory vaccines, and the company continues to invest in oncology and other infectious disease platforms. The RTF letter underscores the evolving regulatory environment for mRNA vaccines, but the company’s leadership remains confident that the company can address the FDA’s concerns and resume the U.S. filing process in the near future.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.